We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+71.22%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$327M
Cap. Flow
+$45.1M
Cap. Flow %
6.18%
Top 10 Hldgs %
57.09%
Holding
84
New
23
Increased
22
Reduced
20
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$40.8M
2
UTHR icon
United Therapeutics
UTHR
+$26.2M
3
HSKA
Heska Corp
HSKA
+$20M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.2M
5
AZN icon
AstraZeneca
AZN
+$10.8M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$29.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$27.8M
3
DHR icon
Danaher
DHR
+$20.4M
4
APLS
Apellis Pharmaceuticals
APLS
+$15.4M
5
GSK icon
GSK
GSK
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.4%
2 Miscellaneous 16.98%
3 Communication Services 1.62%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARO
26
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$6.99M 0.96%
105,169
+28,710
+38% +$1.93M
PCRX icon
27
Pacira BioSciences
PCRX
$1.03B
$6.96M 0.95%
+132,655
New +$5.54M
MYOK
28
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$6.82M 0.94%
70,594
+42,842
+154% +$3.57M
OXFD
29
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$4.55M 0.62%
350,138
+177,945
+103% +$2.14M
AFMD
30
DELISTED
Affimed
AFMD
$4.35M 0.6%
94,299
+38,219
+68% +$1.06M
AMRX icon
31
Amneal Pharmaceuticals
AMRX
$6.11B
$4.22M 0.58%
+886,587
New +$3.65M
AUTL
32
Autolus Therapeutics
AUTL
$623M
$4.14M 0.57%
258,360
+48,347
+23% +$536K
MNTA
33
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.14M 0.57%
124,338
-22,212
-15% -$707K
QGEN icon
34
Qiagen
QGEN
$8.9B
$3.53M 0.48%
+77,770
New +$3.48M
CYTK icon
35
Cytokinetics
CYTK
$10B
$3.34M 0.46%
141,700
-40,000
-22% -$750K
DRNA
36
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.27M 0.45%
128,905
+69,131
+116% +$1.49M
RDUS
37
DELISTED
Radius Health, Inc.
RDUS
$3M 0.41%
220,110
-80,963
-27% -$1.11M
HCA icon
38
HCA Healthcare
HCA
$90.5B
$2.95M 0.4%
30,400
-70,600
-70% -$7.34M
VAPO
39
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$2.94M 0.4%
+8,977
New +$1.89M
ALGN icon
40
PUT
Align Technology
ALGN
$11.2B
$2.74M 0.38%
10,000
– –
DXCM icon
41
DexCom
DXCM
$34.3B
$2.7M 0.37%
26,680
-51,468
-66% -$4.6M
BDSI
42
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.54M 0.35%
583,504
+460,802
+376% +$2.07M
SNY icon
43
Sanofi
SNY
$107B
$2.54M 0.35%
49,778
-139,800
-74% -$6.79M
CCXI
44
DELISTED
ChemoCentryx, Inc.
CCXI
$2.35M 0.32%
40,842
-539,169
-93% -$29.3M
CNCE
45
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$2.32M 0.32%
+232,983
New +$2.23M
PNTG icon
46
Pennant Group
PNTG
$1.3B
$2.32M 0.32%
102,568
-179,613
-64% -$3.76M
OTIC
47
DELISTED
Otonomy, Inc.
OTIC
$2.18M 0.3%
601,163
+39,426
+7% +$103K
KNSA icon
48
Kiniksa Pharmaceuticals
KNSA
$6.09B
$2.08M 0.29%
+81,700
New +$1.71M
ALBO
49
DELISTED
Albireo Pharma Inc
ALBO
$2.07M 0.28%
78,029
– –
LAB icon
50
Standard BioTools
LAB
$252M
$1.88M 0.26%
+467,923
New +$1.63M
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Eversept Partners held 84 positions worth $729M, up 81% from $402M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Eversept Partners deployed $45.1M of net new capital in Q2 2020, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was ChemoCentryx, Inc., an estimated $29.3M trimmed.

  • Eversept Partners's largest Q2 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
  • Eversept Partners added most to Heska Corp in Q2 2020, an estimated $20M increase.
  • Eversept Partners's biggest Q2 2020 reduction was ChemoCentryx, Inc., cutting an estimated $29.3M.
  • Eversept Partners fully exited Kadmon Holdings, Inc. in Q2 2020, selling an estimated $4.09M.
  • Eversept Partners's ten largest holdings make up 57% of its $729M portfolio in Q2 2020.
  • Eversept Partners opened 23 new positions and closed 15 in Q2 2020.
  • Eversept Partners's portfolio value rose 81% quarter-over-quarter to $729M.

Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.